URCC NCORP Research Base

URCC NCORP研究基地

• 批准号: 10240646
• 负责人: KAREN M. MUSTIAN
• 金额: $ 586.35万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10240646
• 关键词: Achievement; Age; American Society of Clinical Oncology; Award; Behavioral; Biological; Biological Markers; Cancer Center; Cancer Control; Cancer Control Research; Cancer Patient; Cancer Survivor; Caregivers; Caring; Clinic; Clinical; Clinical Cancer Center; Clinical Oncology; Clinical Research; Clinical Research Associate; Clinical Trials; Cluster randomized trial; Collection; Committee Members; Communities; Community Clinical Oncology Program; Community Networks; Conduct Clinical Trials; Data; Development; Enrollment; Epigenetic Process; Ethics; Ethnic Origin; Etiology; Funding; Gender; Goals; Grant; Immunologics; Immunotherapy; Individual; Innovative Therapy; Institutes; Intervention; Journals; Knowledge; Leadership; Malignant Neoplasms; Manuscripts; Medical Oncologist; Mentors; Minority; Minority Groups; Modernization; Morbidity - disease rate; NCI Center for Cancer Research; National Cancer Institute; Nature; Nurses; Oncologist; Oncology; Operative Surgical Procedures; Outcome; Pathway interactions; Patient Care; Patients; Peer Review; Phase; Physicians; Physiological; Pilot Projects; Positioning Attribute; Prevalence; Procedures; Productivity; Program Development; Prospective cohort study; Protocols documentation; Publications; Publishing; Quality of Care; Race; Radiation Oncologist; Radiation therapy; Randomized; Randomized Clinical Trials; Reporting; Research; Research Personnel; Resources; Risk; Scientific Inquiry; Severities; Sex Orientation; Site; Supportive care; Surgeon; Survivors; Symptoms; System; Testing; Time; Toxic effect; Training; Treatment Side Effects; Treatment-related toxicity; Underserved Population; United States; Universities; Vision; Woman; Work; anticancer research; base; cancer care; cancer therapy; care delivery; chemotherapy; clinical care; data acquisition; design; experience; gene therapy; health disparity; health equity; hormone therapy; human subject protection; improved; innovation; investigator training; member; novel; participant enrollment; programs; psychosocial; recruit; side effect; stem; symptom science; system-level barriers; treatment guidelines; virtual

ABSTRACT: The University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base (RB) is a RB with 35+ years of experience conducting cancer control research (CCR) and cancer care delivery research (CCDR). The URCC NCORP RB’s vision is "to help good people through lousy times when they experience cancer” by reducing cancer- and treatment- related morbidity stemming from toxicities and side effects. Since 2014, 35% (N=2,831) of all NCORP accrual credits resulted from enrollment of patients and survivors by our Community Affiliates on our 13 active URCC clinical trials. URCC and its Community Affiliates also enrolled 421 caregivers and more than 300 oncologists to our 13 active trials, as well as 1,752 patients and survivors to our 29 local pilot studies. URCC successfully enrolled and randomized over 30 individual community oncology practices to cluster randomized trials. Our investigators and staff submitted 8 new concepts/grants, with 18 new concepts/grants currently in development, and 29 active pilot studies. The significant and innovative contribution of URCC research to scientific knowledge and clinical care is evidenced by 1) 197 published manuscripts, 2) 209 presented abstracts, 3) 25 podium presentations at ASCO, 4) 82 outstanding research awards to our investigators, 5) 12 junior investigators successfully trained to conduct research in NCORP, and 6) 2,215 investigators, clinicians, and staff successfully trained to implement URCC NCORP RB protocols at community sites across the United States. Notable recognition of the significance of research conducted by the URCC RB and its investigators includes: 1) Best of JCO publication for 2017, 2) most cited article in JAMA Oncology for 2017, 3) one of the most significant advances in cancer research and care for 2018, 4) citation of our published research in virtually all existing supportive care treatment guidelines, and 5) leadership by 5 of our RB Executive Committee members in the development of 4 supportive care treatment guidelines. We accomplish our goal of reducing cancer- and treatment-related morbidity by working with cancer patients, survivors, and their caregivers from 592 community oncology practices across the United States to design and conduct CCR and CCDR, including translational and health equity outcomes, focused in symptom science. Our research develops and tests novel treatments for toxicities and side effects stemming from cancer and its treatments. We design and conduct phase I-III randomized clinical trials and longitudinal, prospective cohort studies. To meet its responsibilities as a RB and maintain its high level of productivity over the next funding period, the URCC RB will focus its resources and expertise on the following specific aims: Aim 1) to conduct CCR, Aim 2) to conduct CCDR, Aim 3) to conduct translational CCR, Aim 4) to conduct health equity CCR and CCDR, and Aim 5) to provide state-of-the-art training and mentoring for NCORP investigators and staff. With its proven track record of productivity and innovation, the URCC NCORP RB is expertly positioned to continue its pioneering symptom science research in the NCORP Network.

摘要：美国罗切斯特大学癌症中心（URCC）国家癌症研究所社区 肿瘤学研究计划（NCORP）研究基地（RB）是一个拥有35年以上经验的RB， 癌症控制研究（CCR）和癌症护理提供研究（CCDR）。URCC NCORP RB的愿景是 “帮助好人度过他们患癌症的糟糕时期”，通过减少癌症和治疗， 与毒性和副作用有关的发病率。自2014年以来，所有NCORP累积的35%（N= 2，831） 我们的社区附属机构在我们的13个活跃URCC上招募患者和幸存者所产生的学分 临床试验URCC及其社区附属机构还招募了421名护理人员和300多名肿瘤学家， 我们的13项正在进行的试验，以及1，752名患者和幸存者参加了我们的29项当地试点研究。URCC成功 招募并随机分配了30多个个体社区肿瘤学实践，以进行群集随机试验。我们 调查员和工作人员提交了8个新概念/赠款，18个新概念/赠款目前正在开发中， 和29项试点研究。URCC研究对科学知识的重大和创新贡献 和临床护理证明了1）197发表的手稿，2）209提出的摘要，3）25讲台 在ASCO的演讲，4）82个杰出的研究奖给我们的研究人员，5）12个初级研究人员 成功培训在NCORP中进行研究，6）2，215名研究者，临床医生和工作人员成功 接受培训，在美国各地的社区站点实施URCC NCORP RB协议。显著 对URCC RB及其调查人员进行的研究的重要性的认识包括：1）最好的 2017年JCO出版物，2）2017年JAMA Oncology中引用最多的文章，3）最重要的进展之一 在2018年的癌症研究和护理中，4）引用我们在几乎所有现有支持性护理中发表的研究 治疗指南，以及5）由我们的RB执行委员会5名成员领导制定4 支持性护理治疗指南。我们实现了减少癌症和治疗相关的 通过与来自592个社区肿瘤学实践的癌症患者、幸存者及其照顾者合作， 设计和实施CCR和CCDR，包括转化和健康公平 结果，专注于症状科学。我们的研究开发和测试新的治疗毒性， 癌症及其治疗的副作用。我们设计并进行了I-III期随机临床试验， 试验和纵向前瞻性队列研究。履行其作为RB的职责并保持其高水平 为了在下一个资助期内提高生产力，城市资源协调委员会经常预算将把其资源和专门知识集中在以下方面 具体目标：目标1）进行CCR，目标2）进行CCDR，目标3）进行翻译CCR，目标4） 进行卫生公平CCR和CCDR，目标5）为以下人员提供最先进的培训和指导 NCORP调查员和工作人员。凭借其生产力和创新的良好记录，URCC NCORP RB是专业定位，继续其开拓性的症状科学研究在NCORP网络。